skip to main content

Overview

Prostate cancer (PCa) is the most commonly diagnosed cancer in men with an estimated 23,600 new cases in 2013 and it is the third leading cause of cancer-related death in Canadian men.

The Canadian Prostate Cancer Biomarker Network (CPCBN) is a research program directed by a group of clinicians and scientists with the ultimate goal of improving the clinical management of men with prostate cancer.

Tissue samples include:

  • Optimization Tissue MicroArrays (TMAs)
    • Tissues from prostate, breast and ovarian cancer
    • Mouse xenograft tissues obtained by injecting PC3, LNCaP, Du145 or 22RV1 cell lines in mice.
  • Validation Test Cohort TMAs
    • 250 radical prostatectomies from PCa patients.
    • Initial cohort.
  • Validation Large Cohort TMAs
    • 1250 radical prostatectomies from PCa patients.
    • Independent cohort.
  • Validation Cohort TMAs
    • Three cores of tumour tissue, two cores of normal adjacent tissue.
    • Multiple centres.
    • Treatment naïve patients.
    • Complete clinical data with follow-up.
    • Clinical data stored in Advance Tissue Management (ATiM) database.
    • Two cores of xenografts tissue obtained from PC3, LNCaP, Du145 or 22RV1 injection in mice.

Scientific Summary

Note the tab for this links directly to a document 

/docs/default-source/default-document-library/tfri_portfolio_2013_web.pdf

but this area is still required. Do NOT delete

CPCBN Objectives

Biomarker Core

  • Assemble tissue micro-array (TMA) based validation platforms:
    • 1500 radical prostatectomy specimens
    • 250 biopsy specimens from intermediate risk patients treated by radiotherapy
    • 250 biopsy specimens from low risk patients followed by active surveillance
  • Validate biomarkers:
    • Specific to low risk disease that will not progress (biopsy based), to safely follow them by active surveillance and avoid therapeutic complication
    • Specific to patients with a high risk of progression/recurrence to combine their initial treatment with adjuvant therapies
  • Establish a nomogram to facilitate prostate cancer patient management

Knowledge to Action Core

  • Snapshot of active surveillance uptake in Canada for the year 2010
  • Use focus groups to identify the barriers in the offer, acceptance and adherence to active surveillance in Canada
  • Organize a knowledge transfer meeting of TFRI translational projects, to tackle how to transfer scientific discovery to clinical practice as a means of improving health outcomes for patients.

Contact Details

Project co-ordinator:

Dr. Véronique Ouellet: tfri.cpcbn@gmail.com

Participating Biobanks

  • #Centre hospitalier de l'Université de Montreal (CHUM). Drs Fred Saad / Anne-Marie Mes-Masson 
  • Centre hospitalier universitaire de Quebec (CHUQ). Dr. Lacombe 
  • McGill University Health Centre. Drs. Armen Aprikian / Simone Chevalier 
  • University Health Network (UHN) Biobank. Dr. Neil Fleshner 
  • University of British Columbia/ Vancouver Coastal Health Authority. Dr. Martin Gleave 
  • University Health Network (UHN) Biobank. Dr. Robert Bristow
  • Sunnybrook Research Institute. Dr. Laurence Klotz
  • Cancer Care Manitoba. Dr. Drachenberg
  • Réseau de recherche sur le cancer (RRCancer)

Collaborating partners

  • Canadian Tumour Repository Network (CTRNet)
  • Prostate Cancer Canada
  • International Cancer Genome Consortium 
  • Movember

 

Access the CPCBN repository

To access the repository, researchers should complete an application form, which will be assessed by the study committee. All images and results must be returned to the CPCBN on completion of the study.

To submit your completed application, or for more information, please contact Véronique Ouellet.

The information on these webpages and more details about the CPCBN project can be found in the CPCBN pamphlet.

CPCBN application